| 1 |
Wang C, Yang L, Xu S, Guo H, Guan H, Wang Q, Jiang X, Fei M, Zhang J. Systematic analysis of the role and significance of target genes of active ingredients of traditional Chinese medicine injections in the progression and immune microenvironment of hepatocellular carcinoma. Front Pharmacol 2022;13:1095965. [PMID: 36686660 DOI: 10.3389/fphar.2022.1095965] [Reference Citation Analysis]
|
| 2 |
Xu J, Lin S, Hu H, Xing Q, Geng J. Tumor-Targeting Polymer–Drug Conjugate for Liver Cancer Treatment In Vitro. Polymers 2022;14:4515. [DOI: 10.3390/polym14214515] [Reference Citation Analysis]
|
| 3 |
Xie Y, Yan F, Wang X, Yu L, Yan H, Pu Q, Li W, Yang Z. Mechanisms and network pharmacological analysis of Yangyin Fuzheng Jiedu prescription in the treatment of hepatocellular carcinoma. Cancer Med 2023;12:3237-59. [PMID: 36043445 DOI: 10.1002/cam4.5064] [Reference Citation Analysis]
|
| 4 |
Xu J, Liu D, Liu Z, Yang J, Chen H. Mechanism of a Herbal Formula Associated with Prognosis and Immune Infiltration in LIHC: Transcriptomics Analysis and Molecular Dynamics Simulations. Evid Based Complement Alternat Med 2022;2022:6084321. [PMID: 35754689 DOI: 10.1155/2022/6084321] [Reference Citation Analysis]
|
| 5 |
Yang H, Wang L, Zhang J. Leukocyte modulation by natural products from herbal medicines and potential as cancer immunotherapy. J Leukoc Biol 2022. [PMID: 35612275 DOI: 10.1002/JLB.3RU0222-087RRR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 6 |
Liu D, Wang Z, Zhong L, Xie C, Huang X, Zhi Y, Zhang Y, Liang J, Shi Z, Huang J, Zhang S, Zhang J, Ding F, Raza F. Targets and Potential Mechanism of Scutellaria baicalensis in Treatment of Primary Hepatocellular Carcinoma Based on Bioinformatics Analysis. Journal of Oncology 2022;2022:1-19. [DOI: 10.1155/2022/8762717] [Reference Citation Analysis]
|
| 7 |
Yang H, Zhang J, Ling J. The Modulatory Effects and Targets Prediction of Herbal Medicines or Phytochemicals on Cancer Immunosurveillance. Am J Chin Med 2022;50:1401-1422. [DOI: 10.1142/s0192415x22500604] [Reference Citation Analysis]
|
| 8 |
Zhou G, Li Y, Li S, Liu H, Xu F, Lai X, Zhang Q, Xu J, Wan S. Circulating Cell-Free mtDNA Content as a Non-invasive Prognostic Biomarker in HCC Patients Receiving TACE and Traditional Chinese Medicine. Front Genet 2021;12:719451. [PMID: 34603382 DOI: 10.3389/fgene.2021.719451] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Jiang XL, Deng B, Deng SH, Cai M, Ding WJ, Tan ZB, Chen RX, Xu YC, Xu HL, Zhang SW, Zhang SQ, Liu B, Zhang JZ. Dihydrotanshinone I inhibits the growth of hepatoma cells by direct inhibition of Src. Phytomedicine 2021;:153705. [PMID: 34538671 DOI: 10.1016/j.phymed.2021.153705] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 10 |
Pan B, Pan W, Lu Z, Xia C. Pharmacological Mechanisms Underlying the Hepatoprotective Effects of Ecliptae herba on Hepatocellular Carcinoma. Evid Based Complement Alternat Med 2021;2021:5591402. [PMID: 34326886 DOI: 10.1155/2021/5591402] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 11 |
Wu Z, Wei C, Wang L, He L. Determining the Traditional Chinese Medicine (TCM) Syndrome with the Best Prognosis of HBV-Related HCC and Exploring the Related Mechanism Using Network Pharmacology. Evid Based Complement Alternat Med 2021;2021:9991533. [PMID: 34306165 DOI: 10.1155/2021/9991533] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
